Over the last several decades, researchers have developed an understanding of the fundamental role of p53 as a key tumor suppressor, and have been working on new approaches targeting p53 for treating p53‐mutated BC, such as PRIMA‐1, APR‐246, and COTI‐2, which could reactivate mutant p53 (mutp53) to convert it to a form with wild‐type (WT) properties.155, 156, 157. This evidence concerns the gene TP53 and neoplasm.